Cholecystokinin fails to block the spinal inhibitory effects of nociceptin in sham operated and neuropathic rats

European Journal of Pharmacology

Volumn 484, Issue 2-3, 2004, Pages 235-240

  Maie, Idil Ahmed ^a   Dickenson, Anthony H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

(Rat); Cholecystokinin; Electrophysiology; Neuropathic; Nociceptin orphanin FQ; Spinal cord

Indexed keywords

CHOLECYSTOKININ; NOCICEPTIN; OPIATE RECEPTOR; OPIOID RECEPTOR LIKE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; INHIBITION KINETICS; MALE; NERVE FIBER C; NERVE INJURY; NERVE POTENTIAL; NEUROPATHIC PAIN; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SPINAL ANESTHESIA; SPINAL CORD DORSAL HORN; SPINAL NERVE;

EID: 1642505610     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.11.030     Document Type: Article

References (37)

1. Barber N.S., Dourish C.T., Hill D.R. The role of CCK, caerulein, and CCK antagonists in nociception. Pain. 39:1989;307-328.
2. Briscini L., Corradini L., Ongini E., Bertorelli R. Up-regulation of ORL1 receptors in spinal tissue of allodynic rats after sciatic nerve injury. Eur. J. Pharmacol. 447:2002;59-65.
3. Calo' G., Guerrini R., Rizzi A., Salvadori S., Regoli D. Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br. J. Pharmacol. 129:2000;1261-1283.
4. Candeletti S., Guerrini R., Calo' G., Ferri S. Effect of the nociceptin receptor antagonist Phelpsi(CH2NH)-Gly2NC(1-13)NH2 on nociception in rats. 29th International Narcotic Research Conference. 1998;A170 Garmisch-Partenkirchen, Germany.
5. Carpenter K.J., Vithlani M., Dickenson A.H. Unaltered peripheral excitatory action of nociceptin contrast with enhanced spinal inhibitory effects after carrageenan inflammation: an electrophysiological study in the rat. Pain. 85:2000;433-441.
6. Chapman V., Suzuki R., Chamarette H.L., Rygh L.J., Dickenson A.H. Effects of systemic carbamazepine and gabapentin on spinal neuronal responses in spinal nerve ligated rats. Pain. 75:1998;261-272.
7. Devine D.P., Reinscheid R.K., Monsma F.J. Jr., Civelli O., Akil H. The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion. Brain Res. 727:1996;225-229.
8. Faber E.S., Chambers J.P., Evans R.H., Henderson G. Depression of glutamatergic transmission by nociceptin in the neonatal rat hemisected spinal cord preparation in vitro. Br. J. Pharmacol. 119:1996;189-190.
9. Faris P.L., Komisaruk B.R., Watkins L.R., Mayer D.J. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science. 219:1983;310-312.
10. Flatters S.J.L., Fox A.J., Dickenson A.H. Nerve injury induces plasticity that results in spinal inhibitory effects of galanin. Pain. 98:2002;249-258.
11. Garry M.G., Tanelian D.L. Afferent activity in injured nerves. Yaksh T.L., Lynch C. III, Zapol W.M., Maze M., Biebuyck J.F., Saidman L.J. Anesthesia: Biologic Foundations. 1997;531-542 Lippincott-Raven Publishers, Philadelphia, NY.
12. Hao J.X., Xu I.S., Wiesenfeld-Hallin Z., Xu X.-J. Anti-hyperalgesic and anti-allodynic effects of intrathecal nociceptin/orphanin FQ in rats after spinal cord injury, peripheral nerve injury and inflammation. Pain. 76:1998;385-393.
13. Hill D.R., Woodruff G.N. Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365, 260. Brain Res. 526:1990;276-283.
14. Inoue M., Shimohira I., Yoshida A., Zimmer A., Takeshima H., Sakurada T., Ueda H. Nociceptin/orphanin FQ-induced nociceptive responses through substance P released from peripheral nerve endings in mice. J. Pharmacol. Exp. Ther. 291:1999;308-313.
15. Kim S.H., Chung J.M. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain. 50:1992;355-363.
16. 2 with mu and delta opioid antinociception in the rat spinal cord. Neuropeptides. 16:1990;213-218.
17. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., Butour J.L., Guillemot J.C., Ferrara P., Monsarrat B., Mazarguil H., Vassart G., Parmentier M., Costentin J. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature. 377:1995;532-535.
18. Mogil J.S., Grisel J.E., Reinscheid R.K., Civelli O., Belknap J.K., Grandy D.K. Orphanin FQ is a functional anti-opioid peptide. Neuroscience. 75:1996;333-337.
19. Mollereau C., Parmentier M., Mailleux P., Butour J.L., Moisand C., Chalon P., Caput D., Vassart G., Meunier J.C. ORL1, a novel member of the opioid receptor family-Cloning, functional expression and localization. FEBS Lett. 341:1994;33-38.
20. Moran T., Robinson P., Goldrich M.S., McHungh P. Two brain cholecystokinin receptors: implication for behavioural actions. Brain Res. 362:1986;175-179.
21. B antagonist in rats with nerve ligation injury: role of endogenous enkephalins. Neurosci. Lett. 215:1996;161-164.
22. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., Grandy D.K., Langen H., Monsma F.J. Jr., Civelli O. Orphanin FQ: a neuropeptide that activates an opioid like G protein-coupled receptor. Science. 270:1995;792-794.
23. Rossi G.C., Leventhal L., Pasternak G.W. Naloxone sensitive orphanin FQ-induced analgesia in mice. Eur. J. Pharmacol. 311:1996;R7-R8.
24. Schiffmann S.N., Vanderhaeghen J.J. Distribution of cells containing mRNA encoding cholecystokinin in the rat central nervous system. J. Comp. Neurol. 304:1991;219-233.
25. Stanfa L.C., Dickenson A.H. Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenan inflammation. Br. J. Pharmacol. 108:1993;967-973.
26. Stanfa L.C., Dickenson A.H., Xu X.-J., Wiesenfeld-hallin Z. Cholecystokinin and morphine analgesia: variations on a theme. Trends Pharmacol. Sci. 15:1994;65-66.
27. Stanfa L.C., Chapman V., Kerry N., Dickenson A.H. Inhibitory action of nociceptin on spinal dorsal horn neurones of the rat, in vivo. Br. J. Pharmacol. 118:1996;1875-1877.
28. Suzuki R., Chapman V., Dickenson A.H. The effectiveness of spinal and systemic morphine on rat dorsal horn neuronal responses in the spinal nerve ligation model of neuropathic pain. Pain. 80:1999;215-228.
29. Suzuki R., Matthews E.A., Dickenson A.H. Neurobiology of neuropathic pain: mode of action of anticonvulsants. Eur. J. Pain. 6:2002;51-60.
30. Tian J.H., Xu W., Fang Y., Mogil J.S., Grisel J.E., Grandy D.K., Han J.S. Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat. Br. J. Pharmacol. 120:1997;676-680.
31. Wang J.B., Ren M.F., Han J.S. Mobilization of calcium from intracellular stores is one of the mechanisms underlying the antiopioid effect of cholecystokinin octapeptide. Peptide. 13:1992;947-951.
32. Wang J.B., Johnson P.S., Imai Y., Persico A.M., Ozenberger B.A., Epper C.M., Uhl G. cDNA cloning of an orphan receptor gene family member and its splice variant. FEBS Lett. 348:1994;75-79.
33. Watkins L.R., Kinscheck I.B., Kaufman E.F., Miller J., Frenk H., Mayer D.J. Cholecystokinin antagonists selectively potentiate analgesia induced by endogenous opiates. Brain Res. 327:1985;181-190.
34. Williams R.G., Dimaline R., Varro A., Isetta A.M., Trizio D., Dockray G.J. Cholecystokinin octapeptide in rat central nervous system: immunocytochemical studies using a monoclonal antibody that does not react with CGRP. Neurochem. Int. 11:1987;433-442.
35. Xu X.-J., Puke M.J.C., Verge V.M.K., Wiesenfeld-Hallin Z., Hughes J., Hökfelt T. Up-regulation of cholecytokinin in primary sensory neurons is associated with morphine insensitivity in experimental neuropathic pain. Neurosci. Lett. 152:1993;132-139.
36. Xu X.-J., Wiesenfeld-Hallin Z. Novel modulators in nociception. Dickenson A.H., Besson J.-M. In The Pharmacology of Pain. 1997;211-234 Springer-Verlag, Berlin, Germany.
37. Zimmerman M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 16:1983;109-110.